{"id":78795,"date":"2026-09-04T16:37:55","date_gmt":"2026-09-04T08:37:55","guid":{"rendered":"https:\/\/flcube.com\/?p=78795"},"modified":"2026-09-04T16:37:56","modified_gmt":"2026-09-04T08:37:56","slug":"xuanzhu-biopharmaceutical-signs-thailand-commercial-agreement-with-innobic-and-zaoan-for-bireociclib","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78795","title":{"rendered":"Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Xuanzhu Biopharmaceutical (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2575:HKG\">HKG: 2575<\/a>)<\/strong> announced that it has entered into a <strong>tripartite commercial agreement<\/strong> with Thailand-based pharmaceutical company <strong>Innobic (Asia) Co., Ltd.<\/strong> and <strong>ZaoAn International Trading Co., Ltd.<\/strong> regarding the group\u2019s <strong>bireociclib<\/strong> \u2014 the first approved <strong>CDK2\/4\/6 inhibitor<\/strong> in China. The agreement marks a concrete step in the internationalization of Xuanzhu\u2019s flagship oncology asset, establishing a full commercial infrastructure for the Thai market.<\/p>\n\n\n\n<h2 id=\"h-agreement-structure\" class=\"wp-block-heading\">Agreement Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Parties<\/td><td><strong>Xuanzhu Biopharmaceutical (HKG: 2575)<\/strong>, <strong>Innobic (Asia) Co., Ltd.<\/strong> (Thailand), <strong>ZaoAn International Trading Co., Ltd.<\/strong><\/td><\/tr><tr><td>Agreement Type<\/td><td>Tripartite commercial agreement for <strong>bireociclib<\/strong><\/td><\/tr><tr><td>Date<\/td><td>03 Sept 2026<\/td><\/tr><tr><td>Territory<\/td><td><strong>Thailand<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Party<\/th><th>Responsibilities<\/th><\/tr><\/thead><tbody><tr><td><strong>Innobic (Asia)<\/strong><\/td><td>Drug registration, marketing, and commercial operations in Thailand as local distribution partner<\/td><\/tr><tr><td><strong>ZaoAn International<\/strong><\/td><td>Procurement and payment-related responsibilities<\/td><\/tr><tr><td><strong>Xuanzhu Biopharmaceutical<\/strong><\/td><td>Supply of the product as agreed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>bireociclib<\/strong>, the <strong>first approved CDK2\/4\/6 inhibitor in China<\/strong>, developed by <strong>Xuanzhu Biopharmaceutical<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> A unique <strong>multi-target synergistic mechanism of action<\/strong> inhibiting CDK2, CDK4 and CDK6 simultaneously<\/li>\n\n\n\n<li><strong>Efficacy Advantage:<\/strong> Potent inhibition of tumor cell proliferation<\/li>\n\n\n\n<li><strong>Safety Differentiation:<\/strong> Significant reduction in the <strong>hematological toxicities<\/strong> commonly associated with traditional CDK4\/6 inhibitors \u2014 a key limitation of the incumbent class<\/li>\n\n\n\n<li><strong>Therapeutic Position:<\/strong> Dual CDK2 plus CDK4\/6 coverage addresses resistance pathways that emerge under selective CDK4\/6 inhibition<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market entry execution:<\/strong> The tripartite structure pairs <strong>Xuanzhu\u2019s<\/strong> product supply with <strong>Innobic\u2019s<\/strong> established Thai registration and commercial capabilities and <strong>ZaoAn\u2019s<\/strong> trade infrastructure \u2014 a turnkey route to market in Southeast Asia<\/li>\n\n\n\n<li><strong>Geographic expansion:<\/strong> Thailand represents a strategically important beachhead for <strong>bireociclib\u2019s<\/strong> first commercial push beyond China, with potential to anchor broader ASEAN expansion<\/li>\n\n\n\n<li><strong>Competitive positioning:<\/strong> The differentiated safety profile \u2014 particularly reduced hematological toxicity \u2014 gives <strong>bireociclib<\/strong> a compelling story against entrenched CDK4\/6 inhibitors in the Thai breast cancer market<\/li>\n\n\n\n<li><strong>Platform signal:<\/strong> The agreement demonstrates <strong>Xuanzhu Biopharmaceutical\u2019s<\/strong> (HKG: 2575) ability to translate domestic first-in-class approval into international commercial partnerships<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding commercialization plans, regulatory registration in Thailand and market potential are forward-looking and subject to risks and uncertainties, including regulatory approval outcomes, competitive developments and execution risks. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090301345_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026090301345_c.\"><\/object><a id=\"wp-block-file--media-924a42a3-972a-4182-a1a1-cda3e554e767\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090301345_c.pdf\">2026090301345_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/2026090301345_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-924a42a3-972a-4182-a1a1-cda3e554e767\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Xuanzhu Biopharmaceutical (HKG: 2575) announced that it has entered into a tripartite commercial agreement with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[16,4408,1874,670],"class_list":["post-78795","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-hkg-2575","tag-innobic","tag-xuanzhu-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Xuanzhu Biopharmaceutical (HKG: 2575) announced that it has entered into a tripartite commercial agreement with Thailand-based pharmaceutical company Innobic (Asia) Co., Ltd. and ZaoAn International Trading Co., Ltd. regarding the group\u2019s bireociclib \u2014 the first approved CDK2\/4\/6 inhibitor in China. The agreement marks a concrete step in the internationalization of Xuanzhu\u2019s flagship oncology asset, establishing a full commercial infrastructure for the Thai market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78795\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib\" \/>\n<meta property=\"og:description\" content=\"Xuanzhu Biopharmaceutical (HKG: 2575) announced that it has entered into a tripartite commercial agreement with Thailand-based pharmaceutical company Innobic (Asia) Co., Ltd. and ZaoAn International Trading Co., Ltd. regarding the group\u2019s bireociclib \u2014 the first approved CDK2\/4\/6 inhibitor in China. The agreement marks a concrete step in the internationalization of Xuanzhu\u2019s flagship oncology asset, establishing a full commercial infrastructure for the Thai market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78795\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T08:37:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T08:37:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78795#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78795\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib\",\"datePublished\":\"2026-09-04T08:37:55+00:00\",\"dateModified\":\"2026-09-04T08:37:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78795\"},\"wordCount\":391,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"HKG: 2575\",\"Innobic\",\"Xuanzhu Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78795#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78795\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78795\",\"name\":\"Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-04T08:37:55+00:00\",\"dateModified\":\"2026-09-04T08:37:56+00:00\",\"description\":\"Xuanzhu Biopharmaceutical (HKG: 2575) announced that it has entered into a tripartite commercial agreement with Thailand-based pharmaceutical company Innobic (Asia) Co., Ltd. and ZaoAn International Trading Co., Ltd. regarding the group\u2019s bireociclib \u2014 the first approved CDK2\\\/4\\\/6 inhibitor in China. The agreement marks a concrete step in the internationalization of Xuanzhu\u2019s flagship oncology asset, establishing a full commercial infrastructure for the Thai market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78795#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78795\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78795#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib - Insight, China&#039;s Pharmaceutical Industry","description":"Xuanzhu Biopharmaceutical (HKG: 2575) announced that it has entered into a tripartite commercial agreement with Thailand-based pharmaceutical company Innobic (Asia) Co., Ltd. and ZaoAn International Trading Co., Ltd. regarding the group\u2019s bireociclib \u2014 the first approved CDK2\/4\/6 inhibitor in China. The agreement marks a concrete step in the internationalization of Xuanzhu\u2019s flagship oncology asset, establishing a full commercial infrastructure for the Thai market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78795","og_locale":"en_US","og_type":"article","og_title":"Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib","og_description":"Xuanzhu Biopharmaceutical (HKG: 2575) announced that it has entered into a tripartite commercial agreement with Thailand-based pharmaceutical company Innobic (Asia) Co., Ltd. and ZaoAn International Trading Co., Ltd. regarding the group\u2019s bireociclib \u2014 the first approved CDK2\/4\/6 inhibitor in China. The agreement marks a concrete step in the internationalization of Xuanzhu\u2019s flagship oncology asset, establishing a full commercial infrastructure for the Thai market.","og_url":"https:\/\/flcube.com\/?p=78795","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T08:37:55+00:00","article_modified_time":"2026-09-04T08:37:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78795#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78795"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib","datePublished":"2026-09-04T08:37:55+00:00","dateModified":"2026-09-04T08:37:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78795"},"wordCount":391,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","HKG: 2575","Innobic","Xuanzhu Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78795#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78795","url":"https:\/\/flcube.com\/?p=78795","name":"Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-04T08:37:55+00:00","dateModified":"2026-09-04T08:37:56+00:00","description":"Xuanzhu Biopharmaceutical (HKG: 2575) announced that it has entered into a tripartite commercial agreement with Thailand-based pharmaceutical company Innobic (Asia) Co., Ltd. and ZaoAn International Trading Co., Ltd. regarding the group\u2019s bireociclib \u2014 the first approved CDK2\/4\/6 inhibitor in China. The agreement marks a concrete step in the internationalization of Xuanzhu\u2019s flagship oncology asset, establishing a full commercial infrastructure for the Thai market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78795#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78795"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78795#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78795"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78795\/revisions"}],"predecessor-version":[{"id":78797,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78795\/revisions\/78797"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}